Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer

Completed · Phase 2 · Has a placebo group

Conditions studied: Lung Cancer

In brief

RATIONALE: Drugs used in chemotherapy such as paclitaxel and carboplatin use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug, may stop the growth of tumor cells by stopping blood flow to the tumor, and/or may block the enzymes necessary for tumor cell growth. Giving combination chemotherapy with celecoxib before surgery may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well giving paclitaxel together with carboplatin followed by surgery works compared to giving paclitaxel together with carboplatin and celecoxib followed by surgery in treating patients with stage IIIA non-small cell lung cancer.

Key facts

Study ID: NCT00062179
Run by: Jonsson Comprehensive Cancer Center
People needed: 7
Starts: 2003-03-01
Expected to finish: 2006-11-01
Last updated by the study team: 2020-08-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients with biopsy proven non-small cell lung cancer clinical stage IIIA
Mediastinoscopy positive N2 disease is mandatory
The disease must be deemed potentially resectable by the thoracic surgeon
Karnofsky performance status > 80%
Pulmonary function must be acceptable for surgery according to institutional standards
Acceptable hepatic, renal and bone marrow function
Total serum bilirubin < ULN
AST and/or ALT < 2.5x ULN
Alkaline phosphatase < 2.5x ULN
Serum creatinine < 2.0 mg/mm3
White blood cell > 3000/mm3
Platelets > 100,000/mm3
Age 18 or older
Willingness to abstain from chronic use of NSAIDs (defined as > 7 days of continuous therapy per month OR defined as frequency of > 3 times per week) for the duration of the study. For those patients on NSAIDs prior to study entry, cessation of the drug for 72 hours prior to study entry is required
Patients on low-dose ASA (<325 mg daily) for prophylaxis of cardiovascular disease prior to study entry may remain on that dose of ASA during this trial
No anticipated chronic use of steroids. Patients may take the inhaled steroids mometasone or fluticasone if medically indicated

You may not qualify if…

Patients with known hypersensitivity or allergic reactions to COX-2 inhibitors, sulfonamides, NSAIDs, or salicylates
Hypersensitivity to paclitaxel
Significant medical or psychiatric illness that would interfere with patient compliance
Prior malignancy within the last 3 years with the exception of non-melanoma skin cancer
Receiving other investigational agents during the course of this study or are < 3 weeks from completion of other clinical trial therapy
Patients with a history of peptic ulcer disease, bleed disorder, irritable bowel disease, inflammatory bowel syndrome, chronic diarrhea or bowel obstruction within 5 years
Patients receiving enzyme-inducing anticonvulsants are ineligible. Patients who require concomitant therapy with NSAIDs or COX-2 inhibitors
Patients with any other serious underlying medical condition that would impair the ability of the patient to receive or comply with protocol treatment
Patients receiving lithium or fluconazole
Pregnant women or women of childbearing potential that refuse to use effective contraception during the period of chemotherapy.
Patients with a significant history of unstable cardiovascular disease
Uncontrolled diabetes mellitus or uncontrolled infection, including HIV or interstitial pneumonia or interstitial fibrosis

Where it is running

Jonsson Comprehensive Cancer Center at UCLA — Los Angeles, California, United States
New York Weill Cornell Cancer Center at Cornell University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.